Alterity Therapeutics (ASX:ATH) EV-to-EBIT: (As of Aug. 02, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:ATH Alterity Therapeutics Ltd ASX:ATH
28 GF Score
Price A$0.55
View Full Analysis

What is Alterity Therapeutics EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Alterity Therapeutics's Enterprise Value is A$69.44 Mil. Alterity Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was A$0.00 Mil. Therefore, Alterity Therapeutics's EV-to-EBIT for today is .

The historical rank and industry rank for Alterity Therapeutics's EV-to-EBIT or its related term are showing as below:

ASX:ATH's EV-to-EBIT is not ranked *
in the Biotechnology industry.
Industry Median: 12.63
* Ranked among companies with meaningful EV-to-EBIT only.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Alterity Therapeutics's Enterprise Value for the quarter that ended in Mar. 2026 was A$97.88 Mil. Alterity Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was A$0.00 Mil. Alterity Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was %.

Alterity Therapeutics  (ASX:ATH) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Alterity Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2026 ) =EBIT / Enterprise Value (Q: Mar. 2026 )
=0/97.8786
= %

Alterity Therapeutics's Enterprise Value for the quarter that ended in Mar. 2026 was A$97.88 Mil.
Alterity Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alterity Therapeutics EV-to-EBIT Related Terms

Alterity Therapeutics EV-to-EBIT Historical Data

* Premium members only.

The historical data trend for Alterity Therapeutics's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alterity Therapeutics EV-to-EBIT Chart

Alterity Therapeutics Annual Data
Trend Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 -0.11 -0.44 -4.12 0.00

Alterity Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.12 0.00 0.00 0.00 0.00

ASX:ATH vs VRTX, REGN, RVMD: EV-to-EBIT Comparison

For the Biotechnology subindustry, Alterity Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alterity Therapeutics EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alterity Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Alterity Therapeutics's EV-to-EBIT falls into.


ASX:ATH
28GF Score
Alterity Therapeutics Ltd ASX:ATH
EV-to-EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alterity Therapeutics EV-to-EBIT Calculation

Alterity Therapeutics's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=69.440/0
=

Alterity Therapeutics's current Enterprise Value is A$69.44 Mil.
Alterity Therapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alterity Therapeutics Business Description

Other Exchanges ATHE:USAPBN:Germany
Address 350 Collins Street, Suite 4, Level 14, Melbourne, VIC, AUS, 3000
Alterity Therapeutics Ltd is a clinical-stage biotechnology company focused on neurodegenerative diseases and the creation of a chemical library of proprietary molecules. Its research and clinical development efforts are focused on Parkinson's disease and related disorders, where it is identifying and developing novel compounds that address the underlying pathology of these disorders by binding and redistributing excess labile iron, reducing alpha-synuclein aggregation, and rescuing neurons in the brain. Its pipeline programs are ATH434-201, ATH434-202, bioMUSE, ATH434, and Drug Discovery. The Group operated in one segment, research and development into Parkinsonian and other neurodegenerative disorders.
28GF Score

Get the complete analysis for ASX:ATH

EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.55
Price